{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T03:27:44Z","timestamp":1789183664028,"version":"build-2803163510"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T00:00:00Z","timestamp":1749600000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100009702","name":"Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico of Milan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009702","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Italian Ministry of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Real-world data comparing patients with atopic dermatitis (AD) initially treated with upadacitinib vs. those previously treated with biologics or other Janus kinase inhibitors are limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To assess clinical outcomes over 52 weeks of treatment with upadacitinib and to compare patients treated with upadacitinib who had previously received T helper 2 (Th2) biologics but discontinued treatment owing to lack of efficacy (group A) with those who were bio-naive or had discontinued these treatments for reasons other than inefficacy (group B).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective multicentre study of 524 patients with moderate-to-severe AD treated with upadacitinib. A propensity score-matching method was used for the subanalysis of 316 patients to compare group A and group B.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A significant clinical improvement starting from week 4 and continuing throughout the study period was observed in the overall population and in both groups A and B. Group B showed greater improvements at later follow-up times, with a higher median Eczema Area and Severity Index (EASI) percentage improvement at week 52 (P = 0.03) and a significantly higher proportion of patients achieving EASI 90 and EASI 100 (representing a \u2265 90% and 100% improvement from baseline, respectively) at week 36 (P =0.02, \u03c7\u00b2 = 9.5). For the Pruritus Numerical Rating Scale (P-NRS) and Sleep Disturbances Numerical Rating Scale (SD-NRS), group B had a significantly greater percentage of patients reporting a score of 0 or 1 at week 52 (P-NRS: P = 0.02, \u03c7\u00b2 = 5.7; SD-NRS: P = 0.049, \u03c7\u00b2 = 3.9). Group B also had a significantly higher percentage of patients reaching minimal disease activity at week 52 (P = 0.01, \u03c7\u00b2 = 6.0).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Upadacitinib proved to be effective in the long term not only as a first-line therapy but also in patients with a history of treatment with a biologic that had been unsuccessful. However, patients in group B consistently demonstrated better clinical responses at later follow-ups, suggesting that individuals who are bio-naive and those who discontinued Th2 biologics for reasons other than inefficacy may respond more favourably to upadacitinib.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ced\/llaf253","type":"journal-article","created":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T07:35:57Z","timestamp":1749540957000},"page":"2153-2162","source":"Crossref","is-referenced-by-count":3,"title":["Effectiveness and safety of upadacitinib in patients with moderate-to-severe atopic dermatitis and prior inefficacy of T helper 2 biologics: a propensity score-matched study"],"prefix":"10.1093","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7188-7310","authenticated-orcid":false,"given":"Francesca","family":"Barei","sequence":"first","affiliation":[{"name":"Dermatology Unit, Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico , Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Chiei-Gallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Narcisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruggero Cascio","family":"Ingurgio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piergiorgio","family":"Malagoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giampiero","family":"Girolomoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Maurelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Pezzolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Sciarrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Gola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manfredi","family":"Magliulo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Savoia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elia","family":"Esposto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna\u00a0G","family":"Burroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Amoruso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittoria Giulia","family":"Bianchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santo R","family":"Mercuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Satolli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Beatrice","family":"De Felici Del Giudice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Pella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Avallone","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico , Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlotta","family":"Gurioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca Maria","family":"Piraccini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Balato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenia\u00a0V","family":"Di\u00a0Brizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa Giuseppa","family":"Angileri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavia Manzo","family":"Margiotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Romanelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariateresa","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario Bruno","family":"Guanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Lauletta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Dastoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cataldo","family":"Patruno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maddalena","family":"Napolitano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Ortoncelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Ribero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo\u00a0V","family":"Marzano","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico , Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia Mariel","family":"Ferrucci","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico , Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,6,11]]},"reference":[{"key":"2025102707130282500_llaf253-B1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41572-018-0001-z","article-title":"Atopic dermatitis","volume":"4","author":"Weidinger","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"2025102707130282500_llaf253-B2","doi-asserted-by":"crossref","first-page":"553","DOI":"10.3390\/jcm13020553","article-title":"Drug survival of upadacitinib and predicting factors of discontinuation in adult patients affected by moderate-to-severe atopic dermatitis: an Italian multicenter analysis","volume":"13","author":"Pezzolo","year":"2024","journal-title":"J Clin Med"},{"key":"2025102707130282500_llaf253-B3","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1111\/all.14631","article-title":"Systemic treatments in the management of atopic dermatitis: a systematic review and meta-analysis","volume":"76","author":"Siegels","year":"2021","journal-title":"Allergy"},{"key":"2025102707130282500_llaf253-B4","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/jdv.14891","article-title":"Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I","volume":"32","author":"Wollenberg","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025102707130282500_llaf253-B5","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1111\/jdv.14888","article-title":"Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II","volume":"32","author":"Wollenberg","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025102707130282500_llaf253-B6","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.jaci.2019.11.025","article-title":"Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial","volume":"145","author":"Guttman-Yassky","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"2025102707130282500_llaf253-B7","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1016\/S0140-6736(21)00589-4","article-title":"Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"397","author":"Reich","year":"2021","journal-title":"Lancet"},{"key":"2025102707130282500_llaf253-B8","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s13555-024-01157-5","article-title":"Upadacitinib rapidly improves patient-reported outcomes in atopic dermatitis: 16-week results from phase 3 clinical trials (Measure Up 1 and 2)","volume":"14","author":"Simpson","year":"2024","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2025102707130282500_llaf253-B9","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.jaci.2021.07.036","article-title":"Upadacitinib plus topical corticosteroids in atopic dermatitis: week 52 AD Up study results","volume":"149","author":"Silverberg","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"2025102707130282500_llaf253-B10","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1001\/jamadermatol.2022.0029","article-title":"Efficacy and safety of upadacitinib in patients with moderate to severe atopic dermatitis: analysis of follow-up data from the Measure Up 1 and Measure Up 2 randomized clinical trials","volume":"158","author":"Simpson","year":"2022","journal-title":"JAMA Dermatol"},{"key":"2025102707130282500_llaf253-B11","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s40261-023-01336-w","article-title":"Comparison of long-term effectiveness and safety of upadacitinib for atopic dermatitis between dupilumab-exposed and dupilumab-na\u00efve patients","volume":"44","author":"Napolitano","year":"2024","journal-title":"Clin Drug Investig"},{"key":"2025102707130282500_llaf253-B12","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1007\/s40257-023-00798-0","article-title":"Long-term effectiveness and safety of upadacitinib for atopic dermatitis in a real-world setting: an interim analysis through 48 weeks of observation","volume":"24","author":"Chiricozzi","year":"2023","journal-title":"Am J Clin Dermatol"},{"key":"2025102707130282500_llaf253-B13","doi-asserted-by":"crossref","first-page":"e152","DOI":"10.1111\/jdv.19507","article-title":"Effectiveness and safety of upadacitinib for moderate-to-severe atopic dermatitis in a real-world setting: a 52-week retrospective study","volume":"38","author":"Gargiulo","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025102707130282500_llaf253-B14","doi-asserted-by":"crossref","first-page":"2310643","DOI":"10.1080\/09546634.2024.2310643","article-title":"Predictive factors for responders to upadacitinib treatment in patients with atopic dermatitis","volume":"35","author":"Hagino","year":"2024","journal-title":"J Dermatolog Treat"},{"key":"2025102707130282500_llaf253-B15","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1001\/jamadermatol.2021.3023","article-title":"Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis: a randomized clinical trial","volume":"157","author":"Blauvelt","year":"2021","journal-title":"JAMA Dermatol"},{"key":"2025102707130282500_llaf253-B16","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.jaad.2023.05.033","article-title":"Efficacy and safety of switching from dupilumab to upadacitinib versus continuous upadacitinib in moderate-to-severe atopic dermatitis: results from an open-label extension of the phase 3, randomized, controlled trial (Heads Up)","volume":"89","author":"Blauvelt","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"2025102707130282500_llaf253-B17","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1111\/jdv.17351","article-title":"Comparative efficacy and safety of systemic therapies used in moderate-to-severe atopic dermatitis: a systematic literature review and network meta-analysis","volume":"35","author":"Silverberg","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025102707130282500_llaf253-B18","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1007\/s13555-023-01000-3","article-title":"Comparative efficacy of targeted systemic therapies for moderate-to-severe atopic dermatitis without topical corticosteroids: an updated network meta-analysis","volume":"13","author":"Silverberg","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2025102707130282500_llaf253-B19","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/j.jaad.2023.08.059","article-title":"Real-world effectiveness and safety of upadacitinib for the treatment of atopic dermatitis in adult patients switched from dupilumab: a multicenter retrospective study","volume":"89","author":"Georgakopoulos","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"2025102707130282500_llaf253-B20","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jdin.2024.03.023","article-title":"Outcomes of systemic Janus kinase inhibitors following prior dupilumab use for atopic dermatitis: an evidence-based review","volume":"16","author":"Sood","year":"2024","journal-title":"JAAD Int"},{"key":"2025102707130282500_llaf253-B21","doi-asserted-by":"crossref","first-page":"adv00872","DOI":"10.2340\/actadv.v103.5243","article-title":"Effectiveness of upadacitinib in patients with atopic dermatitis including those with inadequate response to dupilumab and\/or baricitinib: results from the BioDay Registry","volume":"103","author":"Boesjes","year":"2023","journal-title":"Acta Derm Venereol"},{"key":"2025102707130282500_llaf253-B22","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1097\/BSD.0000000000000932","article-title":"Propensity score matching: a statistical method","volume":"33","author":"Kane","year":"2020","journal-title":"Clin Spine Surg"},{"issue":"Suppl. 2","key":"2025102707130282500_llaf253-B23","doi-asserted-by":"crossref","first-page":"ljac140.022","DOI":"10.1093\/bjd\/ljac140.022","article-title":"Optimizing the management of atopic dermatitis with a new minimal disease activity concept and criteria and consensus-based recommendations for systemic therapy","volume":"188","author":"Silverberg","year":"2023","journal-title":"Br J Dermatol"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llaf253\/63472076\/llaf253.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/50\/11\/2153\/63472076\/llaf253.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/50\/11\/2153\/63472076\/llaf253.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:13:10Z","timestamp":1761563590000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/50\/11\/2153\/8160526"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,11]]},"references-count":23,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,6,11]]},"published-print":{"date-parts":[[2025,10,27]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llaf253","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11]]},"published":{"date-parts":[[2025,6,11]]}}}